Uncontrolled Asthma Referral Form

This is a Donated Service Programme funded by AstraZeneca & developed in collaboration with the NHS England (NHSE) hosted Accelerated Access Collaborative (AAC)

This referral form remains entirely confidential. No information whatsoever is shared with AstraZeneca.

Please note only coded data will be pulled through, please add any missing information via free text

Reason for Referral			
(Please add relevant			
free text)			
Referring			
Organisation			
Date			
Patient Name			
DOB			
NHS No			
Telephone Number (Mobile)			
Telephone Number (Home)			
Address			
Email address			
Ethnic Group			
Main Spoken Language			
Diagnosis			
Description in Patient Recor	Di	ate of Entry	
Asthma Diagnosis		,	
Last Asthma Review			

Description in Patient Record	Date of Entry
Asthma Diagnosis	
Last Asthma Review	
COPD	
Eczema	
Hay Fever	
Chronic Rhinosinusitis	
Nasal Polyps	
Gastro-oesophageal reflux disease (GORD)	
Allergies	
Severe Asthma	
Anxiety/Depression	

Other Diagnosis

Description in Patient Record	Date of Entry
Diabetes	

Job Code: GB-44281 Date of Prep: July 2023

CHD			
Heart Failure			
Hypertension			
Atrial Fibrillation			
Stroke/TIA			
PAD			
CKD			
Obesity			
,			
Exacerbations/Symptom Contro	si.		
	,, 		
Hospital Admission for			
Asthma Number of Asthma			
Exacerbations (last 12m)			
Inhaler (s) technique checked			
oneenea			
Current Acute & Repeat Medica	tion		
Current Acute & Repeat Medica Medication Acute	tion		
Medication	tion Dosage	Quantity	Last Issued On
Medication Acute		Quantity	Last Issued On
Medication Acute Drug		Quantity Quantity	Last Issued On Last Issued On
Medication Acute Drug Repeat	Dosage		
Medication Acute Drug Repeat Drug	Dosage		
Medication Acute Drug Repeat Drug Repeat Drug	Dosage Dosage	Quantity	Last Issued On
Medication Acute Drug Repeat Drug	Dosage		
Medication Acute Drug Repeat Drug Repeat Drug	Dosage Dosage	Quantity	Last Issued On
Medication Acute Drug Repeat Drug Repeat Drug	Dosage Dosage	Quantity	Last Issued On
Medication Acute Drug Repeat Drug Repeat Dispensing Drug	Dosage Dosage	Quantity	Last Issued On

Job Code: GB-44281 Date of Prep: July 2023

Enter information below from Clinical System findings (over the past 12 months)

We need to understand not only the part	tient	's cur	rent p	resc	ription, but how these medicines have
been used. This is particularly important for systemic and inhaled corticosteroids. For the last year,					
please complete the table below:					
Number of SABA inhaler*					
Number of ICS inhaler*					
Number of ICS/LABA inhaler*					
Number of Systemic Corticosteroid					
Maintenance oral steroid (mOCS)?	Υ		N		
mOCS dose					
mOCS duration (approx.)					

Patient Biometrics

Smoking Status	
Pack Year History	
Electronic Cigarettes/Vaping	
O/E Height	
O/E Weight	
BMI	
Chest X-Ray	

Lung Function Tests

	Last 3
Fractionated exhaled Nitric Oxide (FeNO)	
Forced Expiratory Volume FEV ₁ (L)	
Percent Predicted FEV1 (%)	
Forced Vital Capacity, FVC (L)	
Percentage of predicted forced vital capacity (%)	
FEV1/FVC	
Peak Expiratory Flow Rate PEFR (L/min)	
Best Peak Expiratory Flow Rate (L/min)	

Blood Tests

		Last 3	
Eosinophils % Count			
Eosinophils Count			
Last Other Eosinophils Entry			
Enter the highest recorded eos	inophil count		

Vaccinations

Immunisations	

Job Code: GB-44281 Date of Prep: July 2023

^{*}SABA – Short Acting Beta Agonist; ICS – Inhaled Corticosteroid; ICS/LABA – Inhaled Corticosteroid/Long Acting Beta Agonist